Abstract
A number of companies have announced the vaccines for COVID-19 pandemic that has caused extreme poverty, famine, and more than a billion people have lost livelihood all across the globe. Mass production of vaccine Sputnik V is underway at different locations to inoculate population in Russia, Philippines, Vietnam, Brazil, Saudi Arab, and United Arab Emirates (UAE), and India. mRNA based vaccine of Pfizer-BioNTech after passing phase 2 trial is ready for testing on thousands of volunteers. Oxford University-AstraZeneca vaccine is also under phase 3 trial in US, Brazil, and India. In September, Novavax Inc.’s vaccine will be ready for phase 3 trial. By early next year, two billions of doses will be ready of Novavax. Moderna Therapeutics conducting vaccine trial on 30 thousands volunteers, results will be known soon. Hundreds of thousand volunteers have registered already for vaccination in US and other parts of the world. SinoVac Biotech Ltd. has prepared a vaccine “CoronaVac” and inoculating volunteers in Indonesia and Brazil. CanSino Biologics Inc. in phase 2 trial on 508 volunteers found a satisfactory immune response to COVID-19 virus. Apart from vaccine preparation and availability, we provided data for therapy and treatment for COVID-19 and transmission and stability aspect of COVID-19 SARS-Cov-2 virus. The data and results presented in this article are very important and useful in containing, treating, and eliminating the pandemic COVID-19.
Highlights
As of August 10, 2020, a total number of COVID-19 cases reached 20,002,577 and 733,842 deaths were recorded [1] since the airborne outbreak occurred
Mass production of vaccine Sputnik V is underway at different locations to inoculate population in Russia, Philippines, Vietnam, Brazil, Saudi Arab, and United Arab Emirates (UAE), and India. Messenger RNA (mRNA) based vaccine of Pfizer-BioNTech after passing phase 2 trial is ready for testing on thousands of volunteers
Ill patients are being kept on ventilators and in intensive care units (ICU) and treatment is being given case by case to save the lives from COVID-19
Summary
As of August 10, 2020, a total number of COVID-19 cases reached 20,002,577 and 733,842 deaths were recorded [1] since the airborne outbreak occurred. SinoVac using data of earlier (2003) research which was for SARS-Cov-1 to develop vaccine for COVID-19. Both virus are coronavirus and have similarities. Study shows [5] people infected with SARS-Cov-2 lost immunity to the virus in a few months explains the importance of developing a vaccine which can keep a person immune for at least 1 - 2 years. Antibodies do not last long in asymptomatic person or mild infection This is a big challenge for vaccine makers to keep antibodies’ level very high to neutralize the incoming coronavirus. It is not yet clear what level of antibodies is sufficient to keep a person healthy against the infection. Methods of novel coronavirus SARS-Cov-2 containment have been described
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
